title: Phase II study of aclarubicin in patients with breast cancer previously untreated with adriamycin.
authors.forename: S
authors.initials: S
authors.lastname: Kerpel-Fronius
authors.forename: F
authors.initials: F
authors.lastname: Gyergyay
authors.forename: I
authors.initials: I
authors.lastname: Hindy
authors.forename: A
authors.initials: A
authors.lastname: Decker
authors.forename: I
authors.initials: I
authors.lastname: Sawinsky
authors.forename: Z
authors.initials: Z
authors.lastname: Mechl
authors.forename: M
authors.initials: M
authors.lastname: Nekulova
authors.forename: K
authors.initials: K
authors.lastname: Kolariĉ
authors.forename: R
authors.initials: R
authors.lastname: Tomek
authors.forename: J
authors.initials: J
authors.lastname: Röthig
mesh_terms: D015250:Aclarubicin; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009279:Naphthacenes / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D015250:Aclarubicin; D004317:Doxorubicin